Institute of Hematology and Transfusion Medicine — a novel approach of combining comprehensiveness, coordination, innovation and pro-quality measures for improving diagnosis, treatment, patient care, and the advancement of medical science
Abstract
Like in all European countries, Poland has witnessed a continuing rise in healthcare services needed for treating hematological disease. Not only have morbidity rates increased in myeloid and lymphoid malignancies but, in parallel, a dynamic development of diagnostic methods and therapeutic treatments has occurred in recent times. The Institute of Hematology and Transfusion Medicine constitutes a reference centre in Poland committed to delivering scientific-clinical excellence where it undertakes scientific studies and translational research in hematology, transfusion medicine and related disciplines along with providing healthcare services in such fields. This is a modern medical centre focused on coordinating and integrating treatment using new medical technologies. A multidisciplinary strategy to medicine ensures that all necessary specialists are engaged in disease diagnoses and also for defining disease progression stages together with actual treatment, subsequent rehabilitation and follow-up monitoring. By adopting this comprehensive approach, optimal therapeutic solutions are thereby achieved; patients receive coordinated medical healthcare, which above all else, results in faster and more effective treatments. In order to achieve such aims, it is vital that all diagnostic and medical units collaborate, including with those from other medical centres whenever added specialist treatment is required. In addition to standard diagnostics and treatment, the Institute provides highly specialised and innovative treatments that are molecularly targeted, as well as the opportunity of participating in international clinical trials, where innovative and experimental therapies are used on patients with myeloid and lymphoid malignancies. Such trials have enabled the Institute to apply modern immunological and genetic technologies to diagnoses-treatment. Performing such procedures requires a complex and multidisciplinary approach, not just for ensuring correct diagnoses, but for also assessing prognostic-predictive disease markers, making the diagnoses early, preventing complications, selecting appropriate donor-recipients for hematopoietic cell transplants and evaluating the extent of remission. In collaboration with other national centres and those abroad, the Institute is also engaged in complex and coordinated programmes devoted to preserving women’s fertility for those suffering from cancer and who are treated with chemo/radio-therapy. Over recent years, the Institute has invested in furnishing individual laboratories with the latest equipment and specialised instrumentation. Because of its highly specialist staff, the wide experience of hematopathologists and the supporting teams of biologists and biotechnologists, the Institute has at its disposition the vital ‘know-how’ thereby allowing developments from scientific studies to become successfully implemented and commercialised. The dynamic rise in this area has driven the creation of innovative products under the National Smart Specialisation initiative; this giving the Institute a competitive advantage in developing new medical technologies, at both country and international levels.
Keywords: hematologycomprehensivenesscoordinationinnovationqualitypatient
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)